Definitive Contract 75N93024C00039
Ended Awarded Last action
- Contract number
- 75N93024C00039
- Awardee
-
Avantgen Inc. UEI WLNHKNPNT2M7
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $592,751
Award facts
- Opportunity
-
- PHS202401 Solicitation number
- Contract value 100% obligated
- $592,751.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 12 offers Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- San Diego, CA 92121, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Original award | $592,751 |
About this award
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $592,751 firm fixed-price definitive contract to Avantgen Inc. on September 1, 2024, for the development of rabbit monoclonal antibodies targeting Indian flying fox (bat) biomarkers. The contract, which will be performed in San Diego, California, is scheduled for completion by August 31, 2026, and was awarded without set-aside designation. Avantgen Inc., a biotechnology company specializing in advanced diagnostic technologies and monoclonal antibody development, brings substantial expertise in biomedical research and infectious disease diagnostics to this effort.
This contract aligns with NIAID's mission to support research on emerging infectious diseases and zoonotic pathogens, with bats serving as significant reservoirs for numerous viruses of public health concern. Avantgen's established track record includes multiple NIAID contracts focused on developing rabbit monoclonal antibodies for various biomarkers and diagnostic applications, as well as collaborations with leading research institutions. The development of bat biomarker-specific antibodies will likely support surveillance, diagnostic, and research initiatives related to bat-borne infectious agents and contribute to the broader understanding of viral ecology and disease transmission.
Quick answers
Who was awarded contract 75N93024C00039?
75N93024C00039 was awarded to Avantgen Inc. by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on September 1, 2024.
How much is contract 75N93024C00039 worth?
The government has obligated $592,751 on 75N93024C00039.
Was contract 75N93024C00039 competed?
The extent of competition for 75N93024C00039 was full and open competition. The government received 12 offers.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award